Women and Child Health Department, Hematology-Oncology Laboratory, University of Padova, Padova, Italy.
Haematologica. 2013 Apr;98(4):602-10. doi: 10.3324/haematol.2012.070664. Epub 2012 Oct 25.
MicroRNA-34b down-regulation in acute myeloid leukemia was previously shown to induce CREB overexpression, thereby causing leukemia proliferation in vitro and in vivo. The role of microRNA-34b and CREB in patients with myeloid malignancies has never been evaluated. We examined microRNA-34b expression and the methylation status of its promoter in cells from patients diagnosed with myeloid malignancies. We used gene expression profiling to identify signatures of myeloid transformation. We established that microRNA-34b has suppressor ability and that CREB has oncogenic potential in primary bone marrow cell cultures and in vivo. MicroRNA-34b was found to be up-regulated in pediatric patients with juvenile myelomonocytic leukemia (n=17) and myelodysplastic syndromes (n=28), but was down-regulated in acute myeloid leukemia patients at diagnosis (n=112). Our results showed that hypermethylation of the microRNA-34b promoter occurred in 66% of cases of acute myeloid leukemia explaining the low microRNA-34b levels and CREB overexpression, whereas preleukemic myelodysplastic syndromes and juvenile myelomonocytic leukemia were not associated with hypermethylation or CREB overexpression. In paired samples taken from the same patients when they had myelodysplastic syndrome and again during the subsequent acute myeloid leukemia, we confirmed microRNA-34b promoter hypermethylation at leukemia onset, with 103 CREB target genes differentially expressed between the two disease stages. This subset of CREB targets was confirmed to associate with high-risk myelodysplastic syndromes in a separate cohort of patients (n=20). Seventy-eight of these 103 CREB targets were also differentially expressed between healthy samples (n=11) and de novo acute myeloid leukemia (n=72). Further, low microRNA-34b and high CREB expression levels induced aberrant myelopoiesis through CREB-dependent pathways in vitro and in vivo. In conclusion, we suggest that microRNA-34b controls CREB expression and contributes to myeloid transformation from both healthy bone marrow and myelodysplastic syndromes. We identified a subset of CREB target genes that represents a novel transcriptional network that may control myeloid transformation.
先前的研究表明,在急性髓系白血病中下调 microRNA-34b 会导致 CREB 过表达,从而引起体外和体内白血病增殖。microRNA-34b 和 CREB 在髓系恶性肿瘤患者中的作用从未被评估过。我们检查了诊断为髓系恶性肿瘤患者的细胞中 microRNA-34b 的表达和启动子的甲基化状态。我们使用基因表达谱来鉴定髓系转化的特征。我们确定,microRNA-34b 在原代骨髓细胞培养物和体内具有抑制能力,而 CREB 具有致癌潜力。研究发现,在患有青少年骨髓单核细胞白血病(n=17)和骨髓增生异常综合征(n=28)的儿科患者中,microRNA-34b 上调,但在初诊的急性髓系白血病患者中下调(n=112)。我们的结果表明,在 66%的急性髓系白血病病例中,microRNA-34b 启动子发生了高甲基化,解释了低水平的 microRNA-34b 和 CREB 过表达,而前白血病骨髓增生异常综合征和青少年骨髓单核细胞白血病与高甲基化或 CREB 过表达无关。在同一患者从骨髓增生异常综合征转为急性髓系白血病时采集的配对样本中,我们确认了白血病发病时 microRNA-34b 启动子的高甲基化,在两个疾病阶段,有 103 个 CREB 靶基因差异表达。在另一组患者(n=20)中,这一组 CREB 靶基因被证实与高危骨髓增生异常综合征相关。在这 103 个 CREB 靶基因中,有 78 个在健康样本(n=11)和初诊急性髓系白血病(n=72)之间也有差异表达。此外,在体外和体内,低水平的 microRNA-34b 和高水平的 CREB 表达通过 CREB 依赖性途径诱导异常髓系发生。总之,我们认为 microRNA-34b 控制 CREB 的表达,并有助于健康骨髓和骨髓增生异常综合征的髓系转化。我们确定了一组 CREB 靶基因,代表了一个可能控制髓系转化的新转录网络。